Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 177,544 shares, a growth of 571.2% from the July 15th total of 26,452 shares. Based on an average daily trading volume, of 466,302 shares, the short-interest ratio is currently 0.4 days. Approximately 1.2% of the company’s shares are sold short.

Enlivex Therapeutics Stock Down 5.7%

ENLV traded down $0.11 during trading on Wednesday, hitting $1.81. 382,118 shares of the company traded hands, compared to its average volume of 83,315. Enlivex Therapeutics has a one year low of $1.72 and a one year high of $31.50. The stock’s fifty day moving average is $6.69 and its 200 day moving average is $11.78. The firm has a market cap of $30.47 million, a P/E ratio of -0.22 and a beta of 1.60.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ENLV shares. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $247.50.

Institutional Investors Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after buying an additional 156,336 shares in the last quarter. HRT Financial LP grew its stake in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after buying an additional 135,198 shares in the last quarter. Jane Street Group LLC grew its stake in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares in the last quarter. Invesco Ltd. purchased a new position in Enlivex Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Susquehanna International Group LLP bought a new stake in Enlivex Therapeutics during the 3rd quarter valued at $57,000. 1.02% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.